ArticleScientific reports2025
Effective reduction of unnecessary biopsies through a deep-learning-assisted aggressive prostate cancer detector.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Critical appraisal of artificial intelligence studies for prostate cancer detection on MRI.European radiology · 2026Article
- Prioritising Data Quality Governance for AI in Prostate Cancer: A Methodological Proof-of-Concept Study Using Neural Networks for Risk Stratification.Diagnostics (Basel, Switzerland) · 2026Article
- Beyond Total PSA: Clinical Significance of S2,3PSA% in Reducing Unnecessary Prostate Biopsies.International journal of urology : official journal of the Japanese Urological Association · 2026Review
- Decade-long landscape of transrectal ultrasound (TRUS) in prostate cancer research: trends, collaborations, and emerging frontiers.Journal of ultrasound · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Despite being one of the most prevalent cancers, prostate cancer (PCa) shows a significantly high survival rate, provided there is timely detection and treatment. Currently, several screening and diagnostic tests are required to be carried out in order to detect PCa. These tests are often invasive, requiring either a biopsy (Gleason score and ISUP) or blood tests (PSA). Computational methods have been shown to help this process, using multiparametric MRI (mpMRI) data to detect PCa, effectively providing value during the diagnosis and monitoring stages. While delineating lesions requires a high degree of experience and expertise from the radiologists, being subject to a high degree of inter-observer variability, often leading to inconsistent readings, these computational models can leverage the information from mpMRI to locate the lesions with a high degree of certainty. By considering as positive samples only those that have an ISUP≥2 we can train aggressive index lesion detection models. The main advantage of this approach is that, by focusing only on aggressive disease, the output of such a model can also be seen as an indication for biopsy, effectively reducing unnecessary biopsy screenings. In this work, we utilize both the highly heterogeneous ProstateNet dataset, and the PI-CAI dataset, to develop accurate aggressive disease detection models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.